Current challenges in the risk assessment of neuraminidase inhibitor-resistant influenza viruses.
Gubareva
Larisa V
LV
Influenza Division, National Center for Respiratory Infectious Diseases and Immunization, Coordinated Center for Infectious Diseases, Centers for Diseases Control and Prevention, Atlanta, Georgia, USA. LGubareva@cdc.gov
Fry
Alicia M
AM
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004195:Disease Models, Animal; D024882:Drug Resistance, Viral; D005289:Ferrets; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000187:drug effects*; D007251:Influenza, Human / Q000188:drug therapy*; D051379:Mice; D009439:Neuraminidase / Q000037:antagonists & inhibitors*; D009976:Orthomyxoviridae Infections / Q000188:drug therapy; D018570:Risk Assessment
D000998:Antiviral Agents; D009439:Neuraminidase